The company's March 2026 quarter represents a significant operational milestone, with net sales reaching ₹10.23 crores—the highest quarterly revenue on record. Operating profit (PBDIT excluding other income) stood at ₹1.41 crores, translating to an operating margin of 13.78%, also a record high. The quarter's net profit of ₹1.10 crores marks the company's strongest quarterly performance to date, supported by improved operational efficiency and cost management.
Yet beneath this quarterly success lies a more complex narrative. For the full financial year FY25, Crestchem's revenues declined to ₹25.00 crores from ₹21.00 crores in FY24—a reversal that appears inconsistent with the strong quarterly numbers. This discrepancy suggests significant volatility in the company's business operations and raises concerns about the predictability of future earnings.
Financial Performance: A Tale of Two Periods
The March 2026 quarter showcased impressive profitability metrics. The company achieved a gross profit margin of 15.64% and a PAT margin of 10.75%, both representing substantial improvements over historical averages. Operating efficiency improved markedly, with the operating margin expanding to 13.78% from historical levels in the single digits.
Employee costs for the quarter stood at ₹0.35 crores, whilst interest expenses remained minimal at ₹0.01 crores, reflecting the company's debt-free status. Depreciation charges of ₹0.02 crores underscore the relatively light asset base. The effective tax rate for the quarter came in at 29.75%, resulting in a tax provision of ₹0.47 crores on profit before tax of ₹1.58 crores.
However, the annual perspective presents a different picture. FY25 revenues of ₹25.00 crores represent a 19.0% year-on-year decline, whilst net profit remained flat at ₹2.00 crores compared to FY24. The company's operating margin for the full year stood at 12.0%, up from 9.5% in FY24, indicating improved cost management despite the revenue decline. The PAT margin for FY25 came in at 8.0%, down from 9.5% in the previous year.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|
| Revenue (₹ Cr) | 25.00 | 21.00 | 16.00 | 7.00 | 7.00 |
| YoY Growth | +19.0% | +31.2% | +128.6% | 0.0% | +16.7% |
| Net Profit (₹ Cr) | 2.00 | 2.00 | 0.00 | 0.00 | 0.00 |
| Operating Margin | 12.0% | 9.5% | 0.0% | 0.0% | 0.0% |
| PAT Margin | 8.0% | 9.5% | 0.0% | 0.0% | 0.0% |
Capital Efficiency: A Bright Spot Amidst Concerns
Despite the revenue volatility, Crestchem demonstrates exceptional capital efficiency. The company's average return on equity (ROE) stands at an impressive 32.76%, placing it well above industry averages and indicating strong profitability relative to shareholder capital. This high ROE reflects the company's ability to generate substantial returns from its equity base, a significant strength in the specialty chemicals sector where capital intensity can weigh on returns.
The return on capital employed (ROCE) paints an even more compelling picture at 49.58% on average, with the latest reading at 30.63%. This exceptionally high ROCE demonstrates the company's ability to generate strong returns from its total capital base, including both equity and debt. The superior ROCE relative to ROE is particularly noteworthy, suggesting efficient asset utilisation and minimal debt burden.
Balance Sheet Strength: Zero-Debt Profile
Crestchem operates with a completely debt-free balance sheet, with net debt to equity at -0.13, indicating the company is a net cash entity. Long-term debt stands at zero, whilst current liabilities of ₹3.00 crores as of March 2025 consist primarily of trade payables (₹1.90 crores) and other current liabilities (₹0.08 crores). This conservative capital structure provides financial flexibility and insulates the company from interest rate risks.
Shareholder funds have grown consistently from ₹0.92 crores in FY20 to ₹7.48 crores in FY25, reflecting retained earnings accumulation. Current assets of ₹4.31 crores comfortably exceed current liabilities, indicating strong liquidity. Fixed assets remain minimal at ₹0.26 crores, suggesting an asset-light business model.
The company's sales to capital employed ratio averages 4.19x, indicating efficient asset turnover. Cash flow from operations in FY25 stood at ₹1.00 crore, a positive development though down from ₹2.00 crores in FY23. The company invested ₹1.00 crore in FY24, likely in capacity expansion or product development, though investing cash flow returned to zero in FY25.
Specialty Chemicals Sector: Navigating Cyclical Headwinds
The specialty chemicals sector has faced significant headwinds over the past year, with demand volatility, raw material price fluctuations, and intense competition from Chinese manufacturers creating a challenging operating environment. Crestchem's focus on caprylic/capric triglycerides and lactose-free products positions it in niche segments, which can offer higher margins but also expose the company to concentration risk.
The company's product portfolio serves industrial applications, making it susceptible to broader economic cycles and industrial production trends. The development of two new products—capric/caprylic triglycerides and lactose-free variants—in 2016 demonstrated innovation capability, though the absence of recent product launches raises questions about ongoing research and development efforts.
Operational Volatility: The Core Concern
The stark contrast between quarterly and annual performance metrics suggests significant lumpiness in Crestchem's order book and revenue recognition. The March 2026 quarter alone contributed ₹10.23 crores in revenue—representing over 40% of the prior year's full-year revenue of ₹25.00 crores. This concentration raises questions about the sustainability of quarterly results and the predictability of future earnings.
The company's employee cost of just ₹0.35 crores for the quarter (₹1.00 crore for FY25) indicates a lean organisational structure, which whilst cost-efficient, may limit the company's ability to scale operations or pursue aggressive growth strategies.
Peer Comparison: Premium Valuation Despite Challenges
Within the specialty chemicals peer group, Crestchem presents a mixed picture. The company's ROE of 32.76% significantly outpaces peers such as Bhatia Colour (4.97%), Kemistar Corporation (3.22%), and Hardcastle & Waud (4.83%), demonstrating superior capital efficiency. This high ROE justifies some valuation premium, as it indicates the company's ability to generate strong returns on shareholder capital.
| Company | P/E (TTM) | P/BV | ROE % | Debt/Equity | Div Yield % |
|---|---|---|---|---|---|
| Crestchem | 16.76 | 4.61 | 32.76 | -0.13 | 0.81 |
| Bhatia Colour | 16.91 | 0.74 | 4.97 | -0.05 | — |
| Kemistar Corp. | 163.57 | 3.70 | 3.22 | 0.42 | 0.27 |
| Kalpana Industries | 328.31 | 1.79 | 6.40 | 0.70 | — |
| Hardcastle & Waud | 10.72 | 1.04 | 4.83 | -0.03 | — |
However, Crestchem's price-to-book value of 4.61x stands well above peers, most of whom trade below 2x book value. This premium valuation appears difficult to justify given the company's revenue volatility and declining annual performance. The P/E ratio of 16.76x appears reasonable in isolation but becomes concerning when considered alongside the -31.87% one-year stock return and uncertain earnings trajectory.
The company's market capitalisation of ₹36.00 crores ranks it sixth among its peer group, reflecting its micro-cap status. This small size limits liquidity and institutional participation, with institutional holdings at just 0.13%. The absence of mutual fund, FII, or insurance company holdings underscores the company's limited visibility amongst professional investors.
Valuation Analysis: Attractive Metrics, Uncertain Fundamentals
Crestchem's current valuation metrics present a paradox. The company's proprietary valuation grade stands at "Very Attractive," having been upgraded from "Attractive" in September 2025. This assessment reflects the stock's significant decline from its 52-week high of ₹193.00 to the current price of ₹124.00—a fall of 35.75%.
The P/E ratio of 16.76x appears reasonable for a company with Crestchem's ROE profile, particularly when compared to peers trading at multiples exceeding 100x. The EV/EBITDA multiple of 15.19x and EV/EBIT of 15.72x suggest moderate valuations relative to operational earnings. The EV/Sales ratio of 1.36x indicates the market is pricing in limited growth expectations.
The dividend yield of 0.81% provides modest income, with the company having paid ₹1.00 per share with an ex-dividend date of August 13, 2025. The dividend payout ratio of 11.00% suggests conservative capital allocation, with management retaining most earnings for reinvestment.
However, the "Very Attractive" valuation grade must be viewed in context. The stock's 52-week range of ₹73.01 to ₹193.00 demonstrates extreme volatility, with the current price sitting 69.84% above the low but 35.75% below the high. This volatility, combined with uncertain earnings visibility, makes valuation assessment challenging.
Shareholding Pattern: Promoter Stability, Institutional Absence
Crestchem's shareholding pattern reveals a stable promoter base but minimal institutional interest. Promoter holding stood at 29.94% as of December 2025, showing marginal sequential increases of 0.25% from September 2025 and 0.26% from June 2025. The promoter group is led by Mr. Dipak Narendraprasad Patel with 29.2% and Sonal Dushyant Patel with 0.49%.
| Quarter | Promoter % | FII % | MF % | Insurance % | Other DII % | Public % |
|---|---|---|---|---|---|---|
| Dec'25 | 29.94 | 0.00 | 0.00 | 0.00 | 0.13 | 69.93 |
| Sep'25 | 29.69 | 0.00 | 0.00 | 0.00 | 0.13 | 70.18 |
| Jun'25 | 29.43 | 0.00 | 0.00 | 0.00 | 0.13 | 70.44 |
| Mar'25 | 32.22 | 0.00 | 0.00 | 0.00 | 0.13 | 67.65 |
| Dec'24 | 32.11 | 0.00 | 0.00 | 0.00 | 0.13 | 67.76 |
Notably, there is a complete absence of foreign institutional investors (FIIs), mutual funds, and insurance companies. Other domestic institutional investors (DIIs) hold a token 0.13%, unchanged over the past five quarters. The non-institutional public holds 69.93%, reflecting the stock's retail investor base.
The decline in promoter holding from 32.22% in March 2025 to 29.94% in December 2025—a reduction of 2.28 percentage points—warrants attention. Whilst promoters have subsequently increased their stake marginally over the past two quarters, the earlier reduction could signal profit-taking or liquidity needs. Positively, there is no promoter pledging, eliminating concerns about forced selling or financial stress.
Stock Performance: Severe Underperformance Across Timeframes
Crestchem's stock performance over the past year has been disappointing across most timeframes. The one-year return of -31.87% compares unfavourably to the Sensex's -8.40% decline, resulting in negative alpha of -23.47 percentage points. This significant underperformance reflects both company-specific challenges and broader market weakness.
| Period | Crestchem Return | Sensex Return | Alpha |
|---|---|---|---|
| 1 Week | -1.20% | -0.85% | -0.35% |
| 1 Month | +3.80% | -3.51% | +7.31% |
| 3 Months | +33.98% | -8.01% | +41.99% |
| 6 Months | +1.64% | -12.75% | +14.39% |
| YTD | +10.27% | -12.26% | +22.53% |
| 1 Year | -31.87% | -8.40% | -23.47% |
| 3 Years | +62.94% | +18.98% | +43.96% |
| 5 Years | +257.86% | +45.41% | +212.45% |
The stock has also underperformed its specialty chemicals sector peer group, which delivered a 4.17% return over the past year, resulting in sector underperformance of -36.04 percentage points. This suggests company-specific issues beyond broader sector headwinds.
However, longer-term performance tells a more positive story. The three-year return of 62.94% (alpha of +43.96%) and five-year return of 257.86% (alpha of +212.45%) demonstrate the stock's ability to generate substantial wealth over extended periods. The 10-year return of 1,191.67% represents exceptional long-term performance, though this likely reflects the company's transformation from a struggling entity to profitability.
Recent performance shows some stabilisation, with the stock delivering positive returns over one-month (+3.80%), three-month (+33.98%), six-month (+1.64%), and year-to-date (+10.27%) periods, all significantly outperforming the Sensex. This suggests potential trend reversal, though the one-week decline of -1.20% indicates continued volatility.
Technical Analysis: Mildly Bearish Trend with Mixed Signals
The stock currently trades in a "Mildly Bearish" technical trend, having transitioned from "Bearish" on April 15, 2026 at ₹92.20. The stock trades below all major moving averages—5-day (₹124.34), 20-day (₹125.06), 50-day (₹104.84), 100-day (₹100.00), and 200-day (₹113.27)—though the proximity to short-term averages suggests potential resistance levels.
Technical indicators present mixed signals. The weekly MACD shows bullish momentum whilst the monthly MACD remains bearish. RSI provides no clear directional signal. Bollinger Bands indicate mildly bullish sentiment on the weekly chart but mildly bearish on the monthly. The KST indicator is bullish weekly but bearish monthly, whilst Dow Theory suggests mildly bullish trends on both timeframes.
The stock's beta of 1.42 indicates high volatility relative to the market, with 58.24% annualised volatility classifying it as "High Risk Low Return" based on one-year risk-adjusted metrics. This elevated volatility suits only aggressive investors with high risk tolerance.
Investment Thesis: Quality Metrics Meet Execution Concerns
Crestchem's investment thesis rests on several pillars. The company demonstrates exceptional capital efficiency with ROE of 32.76% and ROCE of 49.58%, metrics that place it amongst the best performers in the specialty chemicals sector. The debt-free balance sheet provides financial flexibility and eliminates refinancing risks. The five-year sales CAGR of 29.17% and EBIT CAGR of 22.69% demonstrate historical growth capability.
The company's quality grade of "Below Average" reflects concerns about recent performance deterioration, though the underlying financial metrics remain strong. The financial trend is classified as "Positive" based on the record March 2026 quarter, whilst the technical trend remains "Mildly Bearish," creating a mixed picture.
The proprietary Mojo Score of 37/100 places the stock in "SELL" territory, reflecting concerns about sustainability despite attractive valuation metrics. This score has fluctuated between "Sell" and "Strong Sell" over recent months, indicating persistent fundamental concerns.
Key Strengths & Risk Factors
✓ Key Strengths
- Exceptional Capital Efficiency: ROE of 32.76% and ROCE of 49.58% demonstrate superior profitability and asset utilisation compared to peers
- Zero-Debt Balance Sheet: Net cash position provides financial flexibility and eliminates interest burden, supporting margins
- Record Quarterly Performance: March 2026 quarter delivered highest-ever revenue (₹10.23 crores) and profit (₹1.10 crores)
- Strong Historical Growth: Five-year sales CAGR of 29.17% and EBIT CAGR of 22.69% demonstrate growth capability
- Improving Margins: Operating margin expanded to 13.78% in Q4 FY26, highest on record, indicating operational efficiency gains
- No Promoter Pledging: Zero pledged shares eliminate concerns about forced selling or financial stress
- Attractive Valuation: P/E of 16.76x appears reasonable given ROE profile, particularly versus peers trading at 100x+ multiples
⚠ Key Concerns
- Revenue Volatility: Significant discrepancy between quarterly strength and annual decline raises sustainability questions
- Severe Stock Underperformance: One-year return of -31.87% versus Sensex -8.40% and sector +4.17% indicates loss of investor confidence
- Minimal Institutional Interest: Zero FII, MF, or insurance holdings; only 0.13% institutional ownership limits liquidity
- Micro-Cap Constraints: ₹36 crore market cap limits visibility, liquidity, and access to growth capital
- Promoter Stake Reduction: Decline from 32.22% to 29.94% over past year, though partially reversed recently
- High Volatility: Beta of 1.42 and 58.24% annualised volatility classify stock as high-risk with uncertain reward profile
- Limited Product Diversification: Concentration in caprylic/capric triglycerides exposes company to product-specific demand risks
Outlook: What to Watch
Positive Catalysts
- Sustained Revenue Growth: Ability to maintain Q4 FY26 revenue run-rate in coming quarters would validate business momentum
- Margin Stability: Sustaining 13%+ operating margins would demonstrate structural improvement rather than one-time benefit
- New Product Launches: Innovation in specialty chemicals could diversify revenue streams and reduce concentration risk
- Institutional Interest: Any mutual fund or DII accumulation would improve liquidity and valuation support
- Technical Reversal: Break above ₹125-130 resistance could trigger momentum-based buying
Red Flags to Monitor
- Q1 FY27 Performance: Significant sequential decline would confirm concerns about quarterly result sustainability
- Further Promoter Selling: Continued reduction in promoter stake would signal lack of confidence in business prospects
- Working Capital Deterioration: Negative cash flow from operations would indicate underlying business stress
- Margin Compression: Return to historical single-digit margins would eliminate key investment rationale
- Technical Breakdown: Breach of ₹100 support (100-day MA) could trigger accelerated selling
The Verdict: Attractive Metrics, Uncertain Execution
Score: 37/100
For Fresh Investors: Avoid initiating positions despite attractive valuation metrics. The stark contrast between quarterly strength and annual decline, combined with severe stock underperformance and minimal institutional interest, creates too much uncertainty. The micro-cap nature and high volatility (beta 1.42) make this suitable only for highly aggressive, well-diversified portfolios willing to accept significant risk. Wait for at least 2-3 quarters of consistent performance before considering entry.
For Existing Holders: Consider reducing positions on any strength towards ₹130-135 levels. Whilst the debt-free balance sheet and exceptional ROE/ROCE metrics provide some comfort, the revenue volatility and execution uncertainty warrant caution. Those with high risk tolerance may hold a token position (maximum 1-2% of portfolio) to participate in potential turnaround, but book partial profits to reduce exposure. Set a strict stop-loss at ₹100 (100-day moving average) to limit downside.
Fair Value Estimate: ₹110-120 (11.3% downside from current levels), reflecting uncertainty about sustainability of recent quarterly performance and persistent concerns about revenue visibility despite strong capital efficiency metrics.
Note: ROCE = (EBIT - Other income)/(Capital Employed - Cash - Current Investments)
⚠️ Investment Disclaimer
This article is for educational and informational purposes only and should not be construed as financial advice. Investors should conduct their own due diligence, consider their risk tolerance and investment objectives, and consult with a qualified financial advisor before making any investment decisions. Past performance is not indicative of future results. Investments in micro-cap stocks carry significant risks including limited liquidity, high volatility, and potential for substantial loss of capital.
